Georgiamune Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Georgiamune Inc. - overview
Established
2017
Location
Gaithersburg, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US, and founded in 2017 by CEO Samir Khleif, Georgiamune Inc. operates as a biotechnology company providing immunotherapeutic and immune signaling pathways to fight diseases. In August 2023, Georgiamune Inc. raised USD 75 million in venture funding co-led by General Catalyst Partners and Parker Institute for Cancer Immunotherapy, with participation from Alexandria Venture Investments, Catalio Capital Management, CJNV BioVenture, Mubadala Capital, and Verition Fund Management.
Georgiamune Inc. provides medical solutions for cancer, autoimmune, antibody, and small molecules such as GIM-122, GIM-531, GIM-407, GIM-0616, GIM-0915, GIM-0710, GIM-0228, and GIM-1213s. The company provides a platform for supporting patients with cancer and autoimmune diseases. In addition, the firm provides research and development services for preclinical and clinical programs.
Current Investors
General Catalyst Partners, Alexandria Venture Investments, Verition Fund Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.georgiamune.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.